Saika Esani

Evaluated 10 oncology startups across diagnostics, medtech, care delivery innovation, and infrastructure; multiple recommendations advanced toward investment decisions.
Built 3 structured diligence memos assessing total addressable market, regulatory exposure, reimbursement dynamics, commercialization risk, and exit pathways.
Contributed to investment thesis development and supported fund positioning discussions with LPs and advisors.
Authored full developer-ready product specification (database schema, FHIR/HL7 integration, HIPAA architecture, user flows across four operational roles) for an AI-driven based platform targeting community oncology practices (details undisclosed due to NDA)

Led customer discovery for AirGenomics (DOE-validated gene-read mapping platform) across healthcare research, biomedical, and agricultural biotech verticals.
Synthesized DOE Phase I customer discovery insights into segment prioritization and positioning recommendations delivered to leadership.
Identified agricultural biotech (seed engineering) as underexplored beachhead market and built the business case for entry.

Scaled team from 4 to 13 people, managing medical review operations across 21 brands and 16+ therapeutic areas (oncology, vaccines, immunology, diabetes, anti-infectives) for Merck’s global promotional portfolio.
Reviewed 1, 000+ promotional and scientific materials with full medical, legal, and regulatory compliance accountability; built domain depth across oncology, anti-infectives, acute care, and antihyperglycemics.
Delivered process improvement engagement for Lundbeck, improving right-first-time rates by 33%; created a standardized comment matrix that reduced error rates by 14%.
Led post-acquisition rebranding for Biocon Canada (Viatris transition); reviewed 50+ documents for regulatory compliance across the antihyperglycemic portfolio.
Managed global cross-functional collaboration across medical affairs, regulatory, brand, and agency teams spanning US, India, and Canada.